Latest Headlines

Latest Headlines

Regeneron doubles down on plant project in Ireland

A couple of years ago, U.S.-based Regeneron said it would turn a former Dell computer plant in Ireland into its production operation outside of the U.S. But with the company booming, what started as a $300 million project needing 300 workers has morphed into a $650 million project that will require 500.

DME data helps Eylea soar in Q2--and poach market share from its Roche rivals

Earlier this year, Regeneron scored a win when its eye drug Eylea outperformed a pair of Roche meds in a head-to-head study. And now, that win is paying off.

Bayer sees Q2 bright spots in China pharma, but consumer health is more complicated

Not so downbeat for Bayer Healthcare in China in the second quarter, though the consumer side like Johnson & Johnson is watching the mix of legacy and new sales channels and managing the integration of products picked up in the acquisition last quarter of Merck's consumer business.

Roche, Novartis and Bayer snag NICE OKs

The U.K.'s cost-effectiveness gatekeeper, the National Institute for Health and Care Excellence (NICE), has bestowed its favor on a crop of new drugs, granting nods to contenders from Roche, Novartis and Bayer.

Report: When it comes to overall patient care, Eylea gets the pricing edge over rival Lucentis

In analyzing post-administration costs, AdverseEvents found that the Roche treatment was significantly pricier, with adverse events costing $25.18 per prescription, versus $8.87 for Eylea.

Bayer nabs new Eylea nod to help it toward 2015 sales target

Bayer said earlier this week that it would be counting on eye blockbuster Eylea to provide some serious sales growth in 2015, and now, it has a new indication the company hopes can help it get there.

Bayer feels sting of mixed decision from NICE for Eylea's use in diabetics

Bayer has won an approval from England's National Institute for Health and Care Excellence (NICE) for its popular eye drug Eylea. But it was a mixed result. The drugmaker offered a discount to get the approval and then NICE granted it for some, but not all, patients with diabetic macular edema.

Regeneron's Eylea beats Roche's Lucentis in new head-to-head study

Regeneron's eye drug Eylea picked up steam against two competing products from Roche, as the first head-to-head study comparing the meds found that Eylea outperformed Lucentis and Avastin in treating moderate to severe vision loss in patients with diabetic macular edema.

Roche boasts new Lucentis approval for retinal damage in diabetes

Roche now has another approval under its belt for eye drug Lucentis. And it's in a market it can call its own: Lucentis is the first U.S.-approved treatment for diabetic retinopathy in patients with diabetic macular edema.

Roche's Lucentis nabs FDA 'breakthrough' tag for diabetic eye disease

Roche's Lucentis may now have a bigger jump on Eylea in diabetic retinopathy. The Swiss drugmaker's Genentech unit won the FDA's "breakthrough" designation for that indication on Monday. And Lucentis was already on the FDA's priority review track, with a decision date in February.